330 related articles for article (PubMed ID: 10209504)
1. Bladder cancer immunogenicity: expression of CD80 and CD86 is insufficient to allow primary CD4+ T cell activation in vitro.
Pettit SJ; Ali S; O'Flaherty E; Griffiths TR; Neal DE; Kirby JA
Clin Exp Immunol; 1999 Apr; 116(1):48-56. PubMed ID: 10209504
[TBL] [Abstract][Full Text] [Related]
2. Endothelial cells modify the costimulatory capacity of transmigrating leukocytes and promote CD28-mediated CD4(+) T cell alloactivation.
Denton MD; Geehan CS; Alexander SI; Sayegh MH; Briscoe DM
J Exp Med; 1999 Aug; 190(4):555-66. PubMed ID: 10449526
[TBL] [Abstract][Full Text] [Related]
3. Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas.
Chaperot L; Plumas J; Jacob MC; Bost F; Molens JP; Sotto JJ; Bensa JC
Exp Hematol; 1999 Mar; 27(3):479-88. PubMed ID: 10089910
[TBL] [Abstract][Full Text] [Related]
4. Differential expression and function of CD80 (B7-1) and CD86 (B7-2) on human peripheral blood monocytes.
Fleischer J; Soeth E; Reiling N; Grage-Griebenow E; Flad HD; Ernst M
Immunology; 1996 Dec; 89(4):592-8. PubMed ID: 9014827
[TBL] [Abstract][Full Text] [Related]
5. Differential function of CD80- and CD86-transfected human melanoma cells in the presence of IL-12 and IFN-gamma.
Rudy W; Gückel B; Siebels M; Lindauer M; Meuer SC; Moebius U
Int Immunol; 1997 Jun; 9(6):853-60. PubMed ID: 9199968
[TBL] [Abstract][Full Text] [Related]
6. Decreased inducible expression of CD80 and CD86 in human monocytes after ultraviolet-B irradiation: its involvement in inactivation of allogenecity.
Fujihara M; Takahashi TA; Azuma M; Ogiso C; Maekawa TL; Yagita H; Okumura K; Sekiguchi S
Blood; 1996 Mar; 87(6):2386-93. PubMed ID: 8630402
[TBL] [Abstract][Full Text] [Related]
7. Human T-cell response to L14 pig cell line transfected with human ligands CD80 and CD86.
Millán O; Rojo I; Juan M; Vilardell C; Yagüe J; Vives J; Martorell J
Transplant Proc; 1999 Sep; 31(6):2630. PubMed ID: 10500750
[No Abstract] [Full Text] [Related]
8. CD80 (B7-1) and CD86 (B7-2) are functionally equivalent in the initiation and maintenance of CD4+ T-cell proliferation after activation with suboptimal doses of PHA.
Vasilevko V; Ghochikyan A; Holterman MJ; Agadjanyan MG
DNA Cell Biol; 2002 Mar; 21(3):137-49. PubMed ID: 12015893
[TBL] [Abstract][Full Text] [Related]
9. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.
Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS
Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960
[TBL] [Abstract][Full Text] [Related]
10. Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition.
Costello RT; Mallet F; Sainty D; Maraninchi D; Gastaut JA; Olive D
Eur J Immunol; 1998 Jan; 28(1):90-103. PubMed ID: 9485189
[TBL] [Abstract][Full Text] [Related]
11. Biased dependency of CD80 versus CD86 in the induction of transcription factors regulating the human IL-2 promoter.
Olsson C; Michaëlsson E; Parra E; Pettersson U; Lando PA; Dohlsten M
Int Immunol; 1998 Apr; 10(4):499-506. PubMed ID: 9620606
[TBL] [Abstract][Full Text] [Related]
12. Human fibroblasts transduced with CD80 or CD86 efficiently trans-costimulate CD4+ and CD8+ T lymphocytes in HLA-restricted reactions: implications for immune augmentation cancer therapy and autoimmunity.
Smythe JA; Fink PD; Logan GJ; Lees J; Rowe PB; Alexander IE
J Immunol; 1999 Sep; 163(6):3239-49. PubMed ID: 10477593
[TBL] [Abstract][Full Text] [Related]
13. The role of T cell costimulation by CD80 in the initiation and maintenance of the immune response to human leukemia.
Matsumoto K; Anasetti C
Leuk Lymphoma; 1999 Nov; 35(5-6):427-35. PubMed ID: 10609780
[TBL] [Abstract][Full Text] [Related]
14. Expression of the CD80 and CD86 molecules enhances cytotoxicity by human natural killer cells.
Luque I; Reyburn H; Strominger JL
Hum Immunol; 2000 Aug; 61(8):721-8. PubMed ID: 10980383
[TBL] [Abstract][Full Text] [Related]
15. Expression and function of the costimulatory molecules B7-1 (CD80) and B7-2 (CD86) in an in vitro model of the human blood--brain barrier.
Omari KI; Dorovini-Zis K
J Neuroimmunol; 2001 Feb; 113(1):129-141. PubMed ID: 11137584
[TBL] [Abstract][Full Text] [Related]
16. Rejection of mouse cardiac allografts by costimulation in trans.
Mandelbrot DA; Kishimoto K; Auchincloss H; Sharpe AH; Sayegh MH
J Immunol; 2001 Aug; 167(3):1174-8. PubMed ID: 11466331
[TBL] [Abstract][Full Text] [Related]
17. Characterization of rat CD80 and CD86 by molecular cloning and mAb.
Maeda K; Sato T; Azuma M; Yagita H; Okumura K
Int Immunol; 1997 Jul; 9(7):993-1000. PubMed ID: 9237108
[TBL] [Abstract][Full Text] [Related]
18. Antigen-presenting T cells induce the development of cytotoxic CD4+ T cells. I. Involvement of the CD80-CD28 adhesion molecules.
Mauri D; Wyss-Coray T; Gallati H; Pichler WJ
J Immunol; 1995 Jul; 155(1):118-27. PubMed ID: 7541409
[TBL] [Abstract][Full Text] [Related]
19. Costimulation regulates the kinetics of interleukin-2 response to bacterial superantigens.
Muraille E; Devos S; Thielemans K; Urbain J; Moser M; Leo O
Immunology; 1996 Oct; 89(2):245-9. PubMed ID: 8943721
[TBL] [Abstract][Full Text] [Related]
20. CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/CD86 expression or T cell alloreactivity.
Vonderheide RH; Butler MO; Liu JF; Battle TE; Hirano N; Gribben JG; Frank DA; Schultze JL; Nadler LM
Int J Oncol; 2001 Oct; 19(4):791-8. PubMed ID: 11562757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
